Document is current
Any future updates will be listed below
-
Authors
de Jong, Madelon M. E. http://orcid.org/0000-0002-6145-6154
Fokkema, Cathelijne
Papazian, Natalie
Czeti, Ágnes
Appelman, Marjolein K.
Vermeulen, Michael
van Heusden, Teddie
Hoogenboezem, Remco M.
van Beek, Gregory
Tahri, Sabrin
Sanders, Mathijs A.
van de Woestijne, Pieter C.
Gay, Francesca
Moreau, Philippe
Büttner-Herold, Maike
Bruns, Heiko
van Duin, Mark
Broijl, Annemiek
Sonneveld, Pieter http://orcid.org/0000-0002-0808-2237
Cupedo, Tom http://orcid.org/0000-0003-1095-4273
-
Funding
Funding for this research was provided by:
International Myeloma Society Paula and Rodger Riney Foundation translational research award
Wilhelm Sander-Stiftung
- License Information
-
More Information
Article History
Received: 24 March 2023
Accepted: 11 March 2024
First Online: 10 April 2024
Competing interests
: M.B.-H. has received speaker’s fees from Sanofi and Pfizer and workshop sponsoring from Novartis. F.G. has received honoraria from Amgen, Celgene, Janssen, Takeda, BMS, AbbVie and GlaxoSmithKline and is on advisory boards for Roche, Adaptive Biotechnologies, Oncopeptides, bluebird bio and Pfizer. P.M. is on advisory boards for and has received honoraria from Janssen. A.B. is on advisory boards for and has received honoraria from Janssen, Sanofi, Amgen and BMS. P.S. has received research funding from Karyopharm, Janssen, Amgen, Celgene and BMS and is on the advisory board for Pfizer. T.C. has received research support from Janssen. The other authors declare no competing interests.
